I love this tech. Gene editing blows my mind. This is just the beginning of this technology. I had to invest in it just to participate. What it will lead to will be amazing. Vertex is an extremely well run company.
The technology seems promising unless there is some big blowup and the government puts a moratorium on it. That's why disruptive tech investing is so tough - many uncontrollable unknown unknowns.
Great video once again! Love the face reveal btw. Would love to hear your opinion on the ginko bioworks fiasco, and what you think of the partnership with nvdia and recursion pharma. Tx !
Glad you enjoyed the video! Our latest Ginkgo piece is here: ru-vid.com/video/%D0%B2%D0%B8%D0%B4%D0%B5%D0%BE-7-cb8SO-d6c.html Our last piece on Recursion is here: ru-vid.com/video/%D0%B2%D0%B8%D0%B4%D0%B5%D0%BE-54yk528JH0A.html
A fascinating video, thanks for this Joe. I think you've really differentiated your content from others on YT with videos like this. It's such a tricky sector to breakdown (or invest in) when you don't have the detailed scientific understanding and background. Just wondering if you've heard much of a company called Humacyte? Any thoughts?
It's a very tricky sector indeed. Subject matter experts are prone to explain things too complex without focusing on the investing aspects while investors can often overlook technical complexity. It's not easy to navigate for sure which is why we took a sort of "spray and pray" approach to investing in gene editing. Humacyte we last covered here (www.nanalyze.com/2022/07/humacyte-stock-regenerative-medicine/) and we're waiting until they have meaningful revenues to take another look. Joe P.
This whole area (genomics) has been a big hole in our pockets, would be nice to finally get a return on my bag of Editas, the others probably never repay their debt
Verve Therapeutics is licensing technology from Beam Therapeutics which is why we haven't been overly interested in the former. Verve's setback in April of this year was also notable. We may look to cover Verve at some point. This is an extremely risky space.
What was it like 3-4 years ago when there was that massive run up? We also trimmed then too because it was outrageously hyped across all gene editing names.
@@Nanalyze for me tue risk has to be worth the reward and it got to the point it no longer was I got called so many names a rider a non believer now those people are buying here to get their average to a 60 dollar on beam and ntla
Our concerns about Ginkgo are numerous, and none of them have to do with M&A speculation: ru-vid.com/video/%D0%B2%D0%B8%D0%B4%D0%B5%D0%BE-7-cb8SO-d6c.html
@@Nanalyze i pivoted the cash I still had in NTLA to LLY so seems to have worked out in the end. What are your thoughts on IOVA? I like it when you cover biotech, wish we had more vids liike this.
Seems like a $2.2 million price tag is spendy but how does that compare to what treatment costs if you don't take CASGEVY? That's the ROI analysis we need to see here (presumably that was considered when deciding on price).
They're likely prioritizing the worst diseases (in terms of impact and life expectancy) that have little to no treatments. Eventually all genetic diseases should be sorted.
